# Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children

> **NCT01245049** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 387 (actual)

## Conditions studied

- Acellular Pertussis
- Poliomyelitis
- Tetanus
- Diphtheria

## Interventions

- **BIOLOGICAL:** Boostrix PolioTM
- **BIOLOGICAL:** RepevaxTM
- **BIOLOGICAL:** PriorixTM

## Key facts

- **NCT ID:** NCT01245049
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-01
- **Primary completion:** 2012-03-27
- **Final completion:** 2012-04-02
- **Target enrollment:** 387 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245049, "Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01245049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*